{"page":{"totalFilteredElements":12},"studies":[{"active":true,"description":"A prospective, non interventional study of tivozanib monotherapy as first-line therapy for patients with advanced renal cell carcinoma and with favorable or intermediate IMDC risk","eudractNumber":null,"id":11560,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T09:28:53+02:00","shortTitle":"Tivoli","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Verbesserung der Versorgungsqualität durch standardisierte Dokumentation d-uo VERSUS","eudractNumber":null,"id":10722,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-11-11T11:39:37+01:00","shortTitle":"Versus","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}